Class Action Lawsuit Filed on Behalf of Checkpoint Therapeutics, Inc. (CKPT) Investors – Nationally Ranked Investors’ Rights Firm Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

Error message

Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

ATLANTA, April 08, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT).

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Monday, April 8, 2024

Information

Tags:

Fraud, CKPT, FDA, BLA, Checkpoint, ISS

Geotags:

ATLANTA, GA, US

Organisation:

HOLZER & HOLZER

Stock Symbol:

NASDAQ:CKPT

Summary

Key Points:

ATLANTA, April 08, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT).
Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021 and 2022, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation.
More information about the firm is available through its website, www.holzerlaw.com , and upon request from the firm.
Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.

ATLANTA, April 08, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT). The lawsuit alleges that Defendants made materially false and misleading statements and/or failed to disclose material adverse information regarding the Company’s business, operations, and compliance policies, including allegations that: (i) Checkpoint had overstated its oversight and/or its establishment of adequate manufacturing standards and controls over, its third-party contract manufacturers; (ii) accordingly, there were one or more issues with the Company’s third-party contract manufacturing organization (“CMO”) for cosibelimab; (iii) all the foregoing reduced the likelihood that the FDA would approve the cosibelimab BLA in its present form; and (iv) as a result, the manufacturing, regulatory, and commercial prospects of cosibelimab were overstated.

If you bought Checkpoint shares March 10, 2021 and December 15, 2023, and suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey Holzer, Esq. at [email protected], by toll-free telephone at (888)-508-6832 or, you may visit the firm’s website at www.holzerlaw.com/case/checkpoint/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is June 4, 2024.

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021 and 2022, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content. 

CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
[email protected]